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New P2Y12 Inhibitors Versus Clopidogrel
in Percutaneous Coronary Intervention
A Meta-Analysis
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Johanne Silvain, MD, Ana Pena, PHD, Guillaume Cayla, MD, Olivier Barthélémy, MD,
Jean-Philippe Collet, MD, PHD, Gilles Montalescot, MD, PHD
Paris, France
Objectives The purpose of this study was to perform a meta-analysis of randomized trials that compare new P2Y12 inhibi-
tors with clopidogrel to determine whether they improve clinical outcomes after percutaneous intervention (PCI).
Background Ticlopidine/clopidogrel prevents major adverse cardiac events after PCI, but no trials have shown an effect on
mortality. New P2Y12 inhibitors are more potent and evaluated in PCI. Whether they decrease mortality after PCI
compared with clopidogrel is unknown.
Methods MEDLINE and Cochrane Controlled Trials Register databases were searched from January 1980 through January
2010. Randomized, placebo-controlled trials that compared new P2Y12 antagonists with clopidogrel in PCI were se-
lected. Data from 8 studies were evaluated and analyses performed for all randomized patients, PCI patients (any
PCI), and PCI for ST-segment elevation myocardial infarction (STEMI) patients. All-cause mortality was the primary
efficacy end point. Thrombolysis In Myocardial Infarction major bleeding was the primary safety end point.
Results A total of 48,599 patients were included with 94% of patients with acute coronary syndrome and 84% of patients
undergoing PCI. New P2Y12 inhibitors significantly decreased death (odds ratio [OR]: 0.83, 95% confidence interval
[CI]: 0.75 to 0.92, p  0.001 for the whole cohort; OR: 0.85, 95% CI: 0.75 to 0.96, p  0.008 for any PCI; and OR:
0.78, 95% CI: 0.66 to 0.92, p  0.003 for PCI for STEMI). In PCI patients, new P2Y12 inhibitors also significantly de-
creased major adverse cardiac events by 18% (p  0.001) and stent thrombosis by 40% (p  0.001). Although there
was an increase in Thrombolysis In Myocardial Infarction major bleeding for any PCI (OR: 1.23, 95% CI: 1.04 to 1.46,
p  0.01), no difference was observed in PCI for STEMI (OR: 0.98, 95% CI: 0.85 to 1.13, p  0.76), with similar out-
comes in primary PCI for STEMI. Results were confirmed in sensitivity analyses that removed the largest study.
Conclusions New P2Y12 inhibitors decrease mortality after PCI compared with clopidogrel. The risk/benefit ratio is particu-
larly favorable in PCI for STEMI patients. (J Am Coll Cardiol 2010;56:1542–51) © 2010 by the American Col-
lege of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.012a
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November 2, 2010:1542–51 P2Y12 Antagonists in PCIbetter tolerance profile than ticlopidine (2), and the benefit
f a loading dose and long-term treatment was suggested in
he CREDO (Clopidogrel for Reduction of Events During
bservation) study (1–3) and confirmed in a meta-analysis
hat combined registries and randomized studies (4).
A survival effect of clopidogrel compared with placebo
as shown in a large randomized non-PCI study performed
n ST-segment elevation myocardial infarction (STEMI)
atients, in which a 7% relative risk decrease in death was
easured at 30 days with clopidogrel 75-mg daily treatment
ombined with aspirin (5). A nonsignificant decrease in
ardiovascular (CV) mortality was also observed with clo-
idogrel at 30 days in STEMI patients treated with fibri-
olysis and undergoing secondary PCI (6). Thus, no single
tudy has shown a decrease in mortality with clopidogrel
hen used in the setting of PCI or in STEMI patients
reated by PCI. A recent study also showed that doubling
he dose of clopidogrel had no impact on mortality in PCI
atients (7,8).
Newly developed P2Y12 inhibitors are more potent and
ave a faster onset of action than clopidogrel, characteristics
hat make them particularly attractive for PCI. Four new
2Y12 inhibitors have now been tested in several clinical
tudies that recruited STEMI, non–ST-segment elevation
cute coronary syndromes, and stable coronary artery disease
atients, predominantly treated with PCI. Each of these
ntagonists has individual properties: prasugrel is an oral
ro-drug leading to irreversible blockade of the P2Y12
eceptor (9), ticagrelor is a direct-acting and reversible
nhibitor of the P2Y12 receptor with potentially more
leiotropic effects (10), cangrelor is an intravenous direct
nd reversible inhibitor of the P2Y12 receptor providing
he highest level of inhibition, and elinogrel is an
ntravenous and oral P2Y12 antagonist with a direct and
eversible action (11). None of the individual studies was
owered to detect a difference in mortality compared with
lopidogrel. However, 1 trial demonstrated a significant
ecrease in mortality in acute coronary syndromes (ACS)
atients, 64.3% of whom underwent PCI (12). We
ypothesized that the benefit of these new agents should
e particularly present when PCI is performed, especially
CI for STEMI, an urgent and high-risk situation in
hich the benefit of fast and potent platelet inhibition is
heoretically of most value. The aim of the present work
as to perform a combined analysis of all the trials
onducted comparing one of these new P2Y12 antagonists
ith clopidogrel. In this way, we have been able to
ncrease the statistical power in addressing the important
uestion of whether there is a decrease in mortality with
hese new agents when used in PCI globally and in PCI
or STEMI in particular.
ethods
tudy objectives, design, and selected trials. The primary
im was to evaluate the effect of new P2Y12 inhibitors (ompared with clopidogrel in
CI patients. We restricted our
nalysis to trials that met all the
ollowing inclusion criteria: 1)
tudy population of coronary pa-
ients with PCI performed at least
n a majority of this population
70%); 2) the reference treat-
ent was clopidogrel or, in the
ase of short half-life intravenous
2Y12 inhibitors, placebo before
lopidogrel administration; and 3)
he report supplied data on both
ortality and bleeding.
We searched MEDLINE and
ochrane Controlled Trials Reg-
ster databases from 1980 to Janu-
ry 2010. Full electronic search
trategy was used, and the terms
sed for research were new P2Y12,
CI, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel.
e used no language restrictions. Furthermore, we
earched reference lists of relevant studies and reviews,
ditorials, and letters on this topic. Full-text articles, sub-
tudies, and meeting abstracts were all included.
The quality of the identified studies was assessed to
nsure minimization of bias. In detail, we evaluated
nformation regarding control for confounders, measure-
ent of exposure, completeness of follow-up, and blind-
ng. No formal scoring system was used. Reviewers were
ot blinded to journal, author, or institution of publica-
ion. With regard to our specific research questions, we
ollected the following variables: clopidogrel and com-
arator loading and maintenance dose and the percentage
nd type of PCI. For STEMI, all types of PCI, primary
CI (within first 24 h of symptom onset), and secondary
CI (24 h after symptom onset) were considered. We
valuated definitions and frequencies of clinical ischemic
vents (all-cause death, CV death, myocardial infarction
MI), stent thrombosis (ST), stroke, MACE, and bleed-
ng outcomes.
Selection, quality assessment, and data extraction of
tudies to be included in this review were all independently
erformed by 3 reviewers (A.B.-A., J.-P.C., and G.M.).
nd points and definitions. The primary efficacy end
oint was all-cause death. We also examined CV death,
ACE, MI, stroke, and ST. MI definitions were those
f the trials concerned and were either the American
ollege of Cardiology/American Heart Association def-
nitions (11,13–15) or the universal definition of MI (12).
tent thrombosis was defined according the Academic
esearch Consortium definitions (16) and reported as
efinite or probable ST, although 1 study used clinical
arget vessel thrombosis (15). The composite end point of
ACE used the definitions of the trials concerned
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CI  confidence interval
CV  cardiovascular
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial InfarctionTable 1).
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P2Y12 Antagonists in PCI November 2, 2010:1542–51The primary safety end point for this meta-analysis was
hrombolysis In Myocardial Infarction (TIMI) non-
oronary artery bypass graft major bleeding, except for 1
mall study in which only major and minor bleeding
ombined were reported (17). For all the other studies,
IMI definitions of bleeding were considered for major or
inor bleeding (18).
All end points were considered at the longest follow-up
vailable in each study (Table 1). Only data from intention-
o-treat cohorts were used for our meta-analysis.
First, a global meta-analysis of all the studies was done,
ncluding all patients regardless of the clinical presentation
nd the treatment with PCI. Then, the PCI meta-analysis
as done, restricting the analyses to the PCI studies and
CI cohorts of studies that had also included medically
reated patients; 2 small studies included in the global
nalysis were excluded in this any PCI analysis data because
CI patients were not individualized (17,19). Finally, a
eta-analysis of PCI for STEMI patients was performed,
estricting the analyses to STEMI patients undergoing
ither primary or secondary PCI. The same analysis was
epeated in STEMI patients undergoing primary PCI
exclusion of secondary PCI patients).
tatistical analysis. We obtained the raw number of pa-
ients experiencing the outcomes of interest among all
atients in each randomized treatment group from each of
he publications of the selected clinical trials. Results are
lternatively presented in text or in graphs.
The common effect calculation was obtained by analyses
f all randomized patients (intention to treat). To give a
lobal estimation of the treatment effect, the results of all
tudies were combined using a random model to minimize
eterogeneity between groups and confirmed by a fixed-
ffects model to avoid small studies being overly weight.
dds ratios (ORs) with 95% confidence intervals (CIs) were
alculated by use of the EasyMa software (20). A 2-tailed
risk of 5% was used for hypothesis testing.
The main objective of the study was to evaluate efficacy
nd safety of the new P2Y12 inhibitors compared with
lopidogrel in the setting of PCI; we performed the analyses
n all types of patients undergoing PCI (any PCI) and in
TEMI patients undergoing PCI (PCI for STEMI). An
dditional analysis was also run for primary PCI for STEMI
atients, restricting the calculation to PCI performed within
4 h of STEMI.
Although the random-effects model accommodated vari-
bility among studies, the extent of heterogeneity in the
rials was also examined. The Q Cochran test was used to
ook for heterogeneity between groups and a 2-tailed p value
f 0.1 was considered as a cutoff for statistical heterogeneity
21). The I2 test for heterogeneity is also reported for each
nd point in the Online Appendix.
A systematic search for publication bias was conducted
sing funnel-plot graphs to check symmetrical distribution
nd convergence toward the pooled effect as the weight of (he trials increased. As none of these graphs suggested
ublication bias, the funnel plots are not shown.
Finally, a sensitivity analysis was done by removing the
argest study when a significant result was observed.
nother sensitivity analysis was performed by removing
he cangrelor studies (intravenous agent with a short
alf-life).
esults
tudies characteristics and global analysis. A flow chart
f the meta-analysis is shown in Figure 1. By subsequent
creening and assessment of titles, abstracts, and full-text
rticles, we included 8 studies that incorporated a total of
8,599 patients (Fig. 2). In those, 94% were ACS patients
nd 84% underwent PCI (Table 1). All trials were random-
zed, double-blind trials, and among them 3 were phase 2
tudies (11,15,19). Five studies compared new oral P2Y12
nhibitors with clopidogrel (12,15,17,19,22), 2 compared a
ew intravenous P2Y12 inhibitor with an intravenous pla-
ebo with pre-PCI clopidogrel administration (11,14), and
compared a new intravenous P2Y12 inhibitor to an
ntravenous placebo with clopidogrel administration after
CI (13). Clopidogrel loading doses varied between 300 mg
15,17,22) and 600 mg (11,13,14,19), and 1 study autho-
ized 300-mg to 600-mg loading doses at the discretion of
he treating clinician (12). Three studies tested prasugrel
15,19,22), 2 studies cangrelor (13,14), 2 others ticagrelor
12,17), and 1 elinogrel (11). Characteristics of these new
2Y12 inhibitors are presented in Table 2. All PCI substud-
es included in the meta-analysis were pre-specified suba-
alyses of the main studies (23,24). The global analysis
egardless of PCI use included 8 studies (11–15,17,19,22),
ith 24,697 patients of 48,599 patients receiving a new
2Y12 inhibitor. There was no significant heterogeneity for
he analyses of any studied end point. New P2Y12 inhibitors
ecreased death by 17% from 3.35% to 2.75% (OR: 0.83,
5% CI: 0.75 to 0.92, p  0.001), CV death by 18% from
.61% to 2.95% (OR: 0.82, 95% CI: 0.72 to 0.92, p 
.001), MACE by 14% from 10.33% to 8.81% (OR: 0.86,
5% CI: 0.8 to 0.93, p  0.001). MI, ST, and target vessel
evascularization were also all significantly decreased. There
as no difference in stroke between groups with 0.83% for
he new P2Y12 inhibitors group and 0.75% for the clopi-
ogrel group (OR: 1.12, 95% CI: 0.92 to 1.37, p  0.27).
here was a significant increase in TIMI major bleeding
rom 1.43% to 1.78% (OR: 1.21, 95% CI: 1.05 to 1.4, p 
.009) and a modest increase in TIMI major or minor
leeding (from 5.2% to 5.73%, OR: 1.15, 95% CI: 1.01 to
.31, p 0.04). Results were confirmed when a fixed-effects
odel was used. In the sensitivity analysis removing studies
ith cangrelor, similar results were obtained (Online
ppendix).
ew P2Y12 inhibitors versus clopidogrel in PCI-treated
atients (any PCI). This analysis included 5 studies
11,13–15,22) and 1 PCI subset of a larger study (24), with
Main Studies and Published Substudies Included in This Meta-AnalysisTable 1 Main Studies and Published Substudies Included in This Meta-Analysis
Study (Ref. #) Year Design n Follow-Up Reference LD/Long Term Comparator Population % PCI MACE Definition
JUMBO (15) 2005 Phase II, RCDB; groups ratio
4:4:5:5
904 30 days Clopidogrel 300 mg/75 mg Prasugrel 60/15 mg,
40/7.5 mg or 60/10
mg
40% UA/NSTEMI, 60% SCAD 99 Death/MI/ST/stroke/hospital*
PRINCIPLE–
TIMI 44 (19)
2007 Phase II RCDB, crossover at
15 days
201 15 days Clopidogrel 600 mg/75 mg Prasugrel 60/10 mg 100% SCAD 55 MACE/CV death/MI/stroke 15 days
TRITON (22) 2007 Phase III RCDB 13,608 15 months Clopidogrel 300 mg/75 mg Prasugrel 60/10 mg 8.1% STEMI,
91.9% UA/NSTEMI
99 CV death/MI/stroke
TRITON STEMI (25)† 2007 Primary PCI 1,438 15 months Clopidogrel 300 mg/75 mg Prasugrel 60/10 mg STEMI 97 CV death/MI/stroke
Secondary PCI 1,094 15 months Clopidogrel 300 mg/75 mg Prasugrel 60/10 mg STEMI
CHAMPION PCI (14) 2009 Phase III RCDB; analysis at 70%
(lack of benefit)
8,716 30 days IV placebo  clopidogrel
600 mg 30 min before
PCI  placebo at the
end of PCI
PO placebo  cangrelor
30-g/kg bolus
30 min before PCI,
4 g/kg/min 2 h,
then clopidogrel
600 mg
11% STEMI, 74% NSTE-ACS,
15% SCAD
98 Death/MI/TVR for ischemia
CHAMPION PCI
STEMI‡
2009 Subanalysis 996 30 days IV placebo  clopidogrel
600 mg 30 min before
PCI  placebo at the
end of PCI
PO placebo  cangrelor
30-g/kg bolus
30 min before PCI,
4 g/kg/min 2 h,
then clopidogrel
600 mg
STEMI 99 Death/MI/TVR for ischemia
CHAMPION
PLATFORM (13)
2009 Phase III RCDB vs. placebo 5,362 30 days IV placebo  clopidogrel
600 mg at the end of
PCI
Cangrelor 30-g/kg
bolus, 4 g/kg/min
2–4 h, then
clopidogrel 600 mg
59% NSTEMI, 35% UA,
5% SCAD
100 Death/MI/TVR for ischemia
DISPERSE2 (17) 2007 Phase II RCDB; 1:1:1; random
for ticagrelor 270 mg LD
984 4 months Clopidogrel 300 mg/75 mg Ticagrelor 90 or 180 mg
twice daily
100% SCAD 42 Death/MI/stroke
PLATO (12) 2009 Phase III RCDB 18,624 12 months Clopidogrel 300–600 mg/
75 mg
Ticagrelor 180 mg LD,
then 90 mg twice
daily
45% STEMI, 43% NSTEMI,
12% UA
64 Death/MI/stroke
PLATO STEMI (27)§ 2009 Phase III RCDB 8,430 12 months Clopidogrel 300–600 mg/
75 mg
Ticagrelor 180 mg LD,
then 90 mg twice
daily
100% STEMI 80 Death/MI/stroke
PLATO Invasive (24)§ 2009 Phase III RCDB 13,408 12 months Clopidogrel 300–600 mg/
75 mg
Ticagrelor 180 mg LD,
then 90 mg twice
daily
49% STEMI, 51% NSTE-ACS 77 Death/MI/stroke
ERASE MI (11) 2009 Phase IIa RCDB vs. placebo;
groups ratio 1:1
70 30 days IV placebo  clopidogrel
600 mg pre-PCI,
300 mg 4 h post-PCI
Elinogrel IV doses
(10 mg/20 mg/
40 or 60 mg) 
clopidogrel 600 mg
before PCI, 300 mg
4 h post-PCI
100% STEMI 91
*Hospitalization for recurrent ischemia. †Subgroup analysis of Wiviott et al. (22). ‡Subgroup analysis of Harrington et al. (14). §Subgroup analysis of Wallentin et al. (12).
CV  cardiovascular; IV  intravenous; LD  loading dose; MACE  major adverse cardiovascular event(s); MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction; NSTE-ACS  non–ST-segment elevation acute coronary syndromes; PCI
 percutaneous coronary intervention; PO oral; RCDB randomized, controlled, double-blind; SCAD stable coronary artery disease; ST stent thrombosis; STEMI ST-segment elevationmyocardial infarction; TVR target vessel revascularization; UA unstable angina. 1545
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P2Y12 Antagonists in PCI November 2, 2010:1542–51total of 42,198 patients (n  21,337 in the new P2Y12
nhibitors group versus n  20,861 in the clopidogrel
roup). Most patients (95%) presented with moderate-to-
igh risk ACS (11,13,14,22), with 1 small study enrolling a
ajority of stable coronary patients (15). Results are pre-
ented in Figure 3. Death was significantly decreased by
5% from 2.89% with clopidogrel to 2.43% with the new
2Y12 inhibitors (p  0.008). Similarly, a significant 13%
ecrease in MACE from 9.99% to 8.61% (p  0.003) and
40% decrease in ST from 1.68% to 1.02% (p  0.001)
ere observed. There was also a significant 16% decrease in
V death from 3.11% to 2.61% (OR: 0.84, 95% CI: 0.72 to
Figure 1 Flow Chart of Study Selection
Of 28 potentially relevant studies identified by our search strategy, only 8 main st
the others were excluded because they did not compare the new P2Y12 with clopid
Figure 2 Size of Studies and Substudies
Included in the Meta-Analysis
The 8 studies, 4 substudies, and the primary percutaneous coronary interven-
tion (PCI) for ST-segment elevation myocardial infarction (STEMI) subgroup of
TRITON considered for analysis are shown.t.96, p  0.01), and a 14% decrease in MI from 7.39% to
.32% (OR: 0.86, 95% CI: 0.74 to 1.01, p  0.07). There
as no difference in stroke between groups with 0.72% with
ew P2Y12 inhibitors versus 0.38% with clopidogrel (OR:
.06, 95% CI: 0.84 to 1.34, p  0.62). There was a
ignificant increase in TIMI major bleeding from 1.28% in
he clopidogrel group to 1.56% in the new P2Y12 inhibitors
roup (OR: 1.23, 95% CI: 1.04 to 1.46, p  0.01), and in
IMI major or minor bleeding, which increased from
.56% with clopidogrel to 3.14% with new P2Y12 inhibitors
OR: 1.25, 95% CI: 1.11 to 1.4, p  0.001). These results
ere confirmed in a fixed-effects model.
In the sensitivity analysis after removal of the largest PCI
tudy (22), the results persisted with significant decreases in
eath (OR: 0.80, 95% CI: 0.69 to 0.73, p  0.003), CV
eath (OR: 0.81, 95% CI: 0.67 to 0.97, p  0.02), MACE
OR: 0.90, 95% CI: 0.81 to 1.00, p  0.05), and ST (OR:
.67, 95% CI: 0.49 to 0.92, p  0.01). There was no
ifference between groups for MI and stroke. TIMI major
leeding did not differ between the 2 groups in this
ensitivity analysis (OR: 1.11, 95% CI: 0.79 to 1.56, p 
.54, but TIMI major or minor bleeding was more frequent
ue to an excess of minor bleeding (OR: 1.19, 95% CI: 1.02
o 1.39, p  0.03). The results were also confirmed after
emoval of patients treated with cangrelor in a sensitivity
nalysis (Online Appendix).
ew P2Y12 inhibitors versus clopidogrel in STEMI
atients treated by PCI (PCI for STEMI). In this anal-
sis, 13,028 STEMI patients were included from 4 studies
hat enrolled such patients (11,14,23,25). Primary or sec-
ndary PCI was performed in 97% of the TRITON (Trial
o Assess Improvement in Therapeutic Outcomes by Op-
nd 4 published substudies were kept for analysis;
or not meet the inclusion criteria. (See the Online Appendix for references.)udies a
ogrelimizing Platelet Inhibition with Prasugrel) STEMI pa-
t
(
n
M
P
a
N
A
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November 2, 2010:1542–51 P2Y12 Antagonists in PCIients (with 69% of primary PCI), 91.4% of the ERASE MI
Early Rapid Reversal of Platelet Thrombosis With Intrave-
ous Elinogrel Before PCI to Optimize Reperfusion in Acute
Figure 3 Effect of New P2Y12 Antagonists on Any PCI
Ninety-five percent of patients presented with moderate-to-high risk acute coronary
death by 15% (from 2.89% to 2.43%, p  0.008), major adverse cardiac events (M
1.68% to 1.02%, p  0.001). They produce a significant increase in Thrombolysis
to 1.46, p  0.01). CI  confidence interval; OR  odds ratio; other abbreviation
ew and Old P2Y12 Inhibitor CharacteristicsTable 2 New and Old P2Y12 Inhibitor Characteristics
P2Y12 Antagonist Type
Mode of
Administration
Clopidogrel Thienopyridine PO
Prasugrel (CS-747) Thienopyridine (new generation) PO
Ticagrelor (AZD-6140) Cyclopentyl-triazolo-pyrimidine PO
Cangrelor (ARC-669931MX) ATP analogue IV
Elinogrel Thienopyridine (PRT060128) IV, PO
TP  adenosine triphosphate; IV  intravenous; PO  oral.yocardial Infarction) patients, 72% of the PLATO (Study of
latelet Inhibition and Patient Outcomes) STEMI patients,
nd 99% of the CHAMPION (Cangrelor versus Standard
omes. Compared with clopidogrel, new P2Y12 inhibitors significantly decreased
by 13% (from 9.99% to 8.61%, p  0.003), and stent thrombosis by 40% (from
ocardial Infarction major bleeding from 1.28% to 1.56% (OR: 1.23, 95% CI: 1.04
Figure 2.
Action Loading Dose/Maintenance
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P2Y12 Antagonists in PCI November 2, 2010:1542–51herapy to Achieve Optimal Management of Platelet Inhibi-
ion) PCI STEMI patients. Results are reported in Figure 4.
his pooled analysis revealed a stronger anti-ischemic effect
han in the previous analysis (any PCI), with a significant 22%
ecrease in death (from 2.56% to 2.09%), a significant 16%
ecrease in MACE (from 5.29% to 4.19%), and a significant
3% decrease in ST (from 3.18% to 2.14%). Similarly, signif-
cant decreases were observed for CV death (from 4.77% to
.89%; OR: 0.81, 95% CI: 0.67 to 0.97, p  0.02) and
I (from 6.45% to 5.04%; OR: 0.81, 95% CI: 0.69 to
.95, p  0.008). There was an increase in stroke (from
.13% to 1.54%, OR: 1.48, 95% CI: 1.07 to 2.07, p 0.02).
ajor bleeding was not different between the 2 groups, nor
Figure 4 Effect of New P2Y12 in PCI for STEMI (Primary and Se
There was a stronger anti-ischemic effect of new P2Y12 antagonists in PCI for STE
2.56% to 2.09%), in MACE by 16% (from 5.29% to 4.19%), and in stent thrombosi
was not different between the 2 groups. Abbreviations as in Figures 2 and 3.as TIMI major or minor bleeding (4.89% vs. 4.78% for Plopidogrel, OR: 1.0, 95% CI: 0.42 to 2.36, p  1.0). All
esults were confirmed with a fixed-effects model.
In a sensitivity analysis excluding the largest dataset
12), these differences persisted with the same magnitude
or death (OR: 0.72, 95% CI: 0.52 to 0.99, p  0.04),
ACE (OR: 0.81, 95% CI: 0.67 to 0.98, p  0.03, and
T (OR: 0.60, 95% CI: 0.39 to 0.93, p  0.02). Similar
rends were observed for CV death (OR: 0.74, 95% CI:
.49 to 1.1, p  0.13), and MI (OR: 0.8, 95% CI: 0.62
o 1.04, p  0.09), and there was no difference in stroke,
IMI major bleeding, and TIMI major or minor bleed-
ng (Fig. 5).
In the additional sensitivity analysis restricted to primary
ary PCI)
n in the any PCI analysis, with a significant decrease in death by 22% (from
3% (from 3.18% to 2.14%). Thrombolysis In Myocardial Infarction major bleedingcond
MI tha
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November 2, 2010:1542–51 P2Y12 Antagonists in PCITEMI study), all the previous results were confirmed (i.e.,
significant decrease in death and all ischemic events,
ithout an increase in major bleeding or TIMI major or
inor bleeding, as shown in Fig. 6).
All results were confirmed in the sensitivity analyses
estricted to PCI for STEMI or primary PCI after removal
f patients treated with cangrelor (Online Appendix).
iscussion
ncreasing loading doses of clopidogrel has been used to
ecrease the time to reach maximal platelet inhibition,
ecrease interindividual variability, and subsequently de-
rease major ischemic events after PCI, without any detect-
ble effect on survival (8,26–29). Greater and more rapid
nhibition of platelet aggregation has become the goal for
ew antiplatelet agents with the expectation of further
mproving outcomes after PCI. A large majority of patients
ecruited in the phase 3 studies that evaluated P2Y12
nhibitors were PCI patients. The main finding of the
resent meta-analysis is the decrease in mortality observed
Figure 5 Effect of New P2Y12 in PCI for STEMI: Sensitivity Ana
The differences observed in Figure 4 persisted with the same magnitude for death
Thrombolysis In Myocardial Infarction major bleeding. CV  cardiovascular; MI  m
Figure 6 Effect of New P2Y12 in Primary PCI for STEMI
All the results observed in STEMI analysis were confirmed with a significant decrea
MACE, and stent thrombosis, without an increase in major bleeding. Abbreviationsith these new P2Y12 inhibitors compared with clopidogrel
hen used in patients treated with PCI. This finding is
urther supported by the significant decreases in death also
bserved in STEMI patients treated by PCI or by primary
CI, 2 smaller groups of patients, but at higher risk and
herefore theoretically obtaining greater benefit from rapid
latelet inhibition for PCI. Additional findings on MACE
nd ST are also in line with the survival benefit.
The new P2Y12 inhibitor agents have in common a
reater potency and a faster onset of action than clopidogrel.
ecause these agents in the same class have individual
roperties and differ from one another, we cannot confirm
ere that the survival effect that we observed in our
eta-analysis is a real class effect. The largest study,
LATO, which assessed ticagrelor therapy, weigh for
1.8% of the patients of the PCI meta-analysis and 64.7% of
he patients of the analysis in STEMI patients, is the one
ith the greatest effect on mortality in PCI (9). However,
hen this study is removed, the same trend is observed with
till a significant 22% decrease in mortality in STEMI
After Removing the PLATO STEMI (Largest Dataset)
E, and stent thrombosis, with no difference in
dial infarction; other abbreviations as in Figures 2, 3, and 4.
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P2Y12 Antagonists in PCI November 2, 2010:1542–51atients treated with PCI. This preponderant benefit ob-
erved in PCI for STEMI and in primary PCI is to be
ighlighted and might be explained by the greatest throm-
otic situation encountered and the need for urgent strong
latelet inhibition. The benefit for mortality of the new
eneration of P2Y12 inhibitors in STEMI patients treated with
CI is consistent across the 3 large studies (7,14,23) included
n this global analysis and is also confirmatory of the observa-
ion made in the TRITON STEMI analysis of a significant
ecrease in mortality with prasugrel at 30 days (1.6% vs. 2.6%;
R: 0.62, 95% CI: 0.39 to 0.99, p  0.04).
Two confounding variables concerning clopidogrel may
ave skewed results in favor of the newer agents. The first
ne is the varying loading doses of clopidogrel (300 mg vs.
00 mg) in the cohorts studied; therefore, it is possible that
ortality in the clopidogrel group was negatively influenced
y inclusion of the 300-mg loading dose, but a subanalysis
ith clopidogrel loading dose 600 mg studies shows
imilar results (significant decrease in death, CV death, and
T in all groups and MACE in global and PCI for STEMI
roups under new P2Y12 antagonists compared with clopi-
ogrel 600 mg). The second is that randomization to the
lopidogrel arm of the trials did not include genotyping for
epatic cytochrome (Cyp2C19) gene variants (present in
5% to 30% of the population) that confer genetic resistance
o clopidogrel and a striking 3-fold increase in risk of ST
nd death (30–34). It is possible that the enhanced efficacy
f newer agents is mostly or only confined to those individ-
als with clopidogrel-resistant alleles. Finally, the high
umber needed to treat for benefit from the newer agents
nd their financial cost compared with clopidogrel’s generic
opies might temper enthusiasm for these agents in the
reater population with the exception of individuals with
TEMI.
Although an excess of major bleeding was noted in the
nalysis done in PCI patients, it disappears in STEMI
atients undergoing PCI. This good safety profile in
TEMI patients undergoing PCI has been reported before
25). Whether this is related to more intense platelet
ctivation in these patients is possible but cannot be shown
ere. It is, however, important to acknowledge that most
TEMI patients have an intracoronary thrombus, whereas
ost non–ST-segment elevation ACS patients do not and
ave less intense platelet activation. Thus, for a similar
ecrease in platelet aggregation, STEMI patients probably
ave still higher levels of platelet aggregation than non–ST-
egment elevation ACS patients, a possible explanation to
he better safety observed in STEMI patients. The excess of
troke restricted to primary PCI of STEMI exposed to the
ewer agents may challenge the net clinical benefit of these
gents. However, the heterogeneity in stroke definitions
cross studies and the absence of such an effect in other
ubgroups also suggest a play of chance for this finding.
tudy limitations. The present work has potential limita-
ions inherent in meta-analyses such as inevitable differences
etween trials (study designs, inclusion criteria, lengths ofollow-up, and end points). The major limitation may be
ue to the disparity of the agent characteristics, as already
oted. Results are not based on individual data, and thus
ata on life-threatening and fatal bleeding are not available.
espite these limitations, a significant improvement in
urvival and other hard clinical outcomes was observed that
re particularly interesting for the STEMI subgroup. In-
eed, there was an apparent gradient for the risk/benefit
atio with a 15% decrease in death in the any PCI analysis,
ncreasing to a 22% decrease in the PCI for STEMI
nalysis. At the same time, major bleeding increased signif-
cantly in the any PCI analysis by 23%, whereas there was
o excess of major bleeding in the PCI for STEMI analysis.
owever, the excessive bleeding seen with the newer agents
epresents a major complication of scheduled PCI and has
een previously linked to poor clinical outcomes including
eath. Finally, we used the longest follow-up available for
ach study, but there were differences between short-term
nd long-term studies that may induce bias in results.
urthermore, the limited 1-year follow-up of the cohorts
rom the individual trials may fail to provide an adequate
ssessment of the substantial safety concerns. However, the
esults show that most of the effects seem to be concentrated
n the first month of follow-up, so we may have decreased
ather than increased the differences by taking the longest
ollow-up reported in each study.
onclusions
n PCI patients, new P2Y12 inhibitors decrease all-cause
ortality and major ischemic events. The net benefit is
articularly marked in PCI for STEMI patients, in which
here is no significant increase in major bleeding when
ompared with clopidogrel.
eprint requests and correspondence: Dr. Gilles Montalescot,
nstitut de Cardiologie, Bureau 2-236, Pitié-Salpêtrière Hospital,
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